MPX to Moderate Panel on “Pharmaceutical Cannabis in Canada”

Event co-hosted by MPX’s pharmaceutical affiliate Salus BioPharma; Explores Current Canadian Climate for Cannabis

TORONTO, Aug. 15, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“MPX” or the “Company”) (CSE: MPX; OTC: MPXEF) today announced that Michael Arnkvarn, its Chief Marketing Officer and General Manager of Canadian Operations will be moderating a panel on  Pharmaceutical Cannabis in Canada on Thursday, August 16, 2018.

Mr. Arnkvarn will present alongside Professor Dedi Meiri, Technician, Integrated Cancer Center and Dr. Keren-Or Amar, Medical Marketing Director, Panaxia, to discuss the current climate for cannabis science and research, its future, as well as to provide an introduction into pharma-grade smokeless medicinal cannabis products.  The discussion will include gaining a better understanding of the differences between pharmaceutical cannabis and medical cannabis and how to bring pharma-grade standards and a new treatment approach into the cannabis industry.

The Company has done several of these medical cannabis educational events in Arizona and is now branching out to Canada.

*Event Details:
Thursday, August 16
Bennett Jones
100 King Street West
Suite 3400
Toronto, ON M5X 14A
5:30 PM – 7:00 PM EDT

Salus BioPharma is a wholly-owned subsidiary of MPX as well as the name of the brand that is manufactured by Panaxia, an Israeli-based pharmaceutical cannabis company that has developed proprietary, smokeless pharma-grade cannabis products, on behalf of MPX. Salus BioPharma products are currently being sold exclusively in Arizona and will soon expand to Canada as well as other states where MPX is present.

David Meiri, PhD, is Associate Professor at the Faculty of Biology at the Technion and a member of the Technion Integrated Cancer Center (TICC). Dr. Meiri holds a M.Sc. in Biochemistry and a Ph.D. in plant biotechnology from Tel Aviv University. He conducted his post-doctoral fellowship at the Ontario Cancer Institute where he focused on tumor invasion and metastasis.

During his post-doctoral studies, Dr. Meiri expanded his knowledge in human biology and cancer pathogenesis and gained worldwide recognition as an expert in the fields of G-protein coupled receptors (GPCRs), small GTPases and cytoskeleton. Upon completion of his post-doctoral fellowship, Dr. Meiri took a position at the Technion Israel Institute of Technology, where he heads the “Laboratory of Cancer Biology and Cannabinoid Research”.

Presently, his lab investigates the therapeutic potential of phytocannabinoids, with focus on the antitumor effects of cannabinoids. In addition to the laboratory cannabis research performed on-site, Dr. Meiri collaborates with cannabis growers, clinicians, major manufacturers and distributors of medical cannabis for the purpose of revolutionizing cannabis treatment. He is operating the “Cannabis Database Project” and his lab is currently involved in eight clinical trials covering diverse aspects of cannabis treatment such as colon disease, pain prevention, cancer treatment and epilepsy.

Dr. Keren-Or Amar joined Panaxia after serving as the General Manager of ShizimXL, a medical devices accelerator and as the business development manager of Cann10, a medical cannabis accelerator. Dr. Amar holds a Ph.D. in life sciences from Bar Ilan University and conducted a Post-Doc research at the Hebrew University in Jerusalem. In addition, Dr. Amar holds an M.A. in law.

To register for the free event, please click on the following link: https://www.eventbrite.com/e/pharmaceutical-cannabis-is-coming-to-canada-tickets-48926498474

To be added to the distribution list, please email MPX@kcsa.com with “MPX” in the subject line.

About MPX Bioceutical Corporation

MPX, through its wholly-owned subsidiaries in the U.S., provides substantial management, staffing, procurement, advisory, financial, real estate rental, logistics and administrative services to three medicinal cannabis enterprises in Arizona operating under the Health for Life (dispensaries) and the award-winning Melting Point Extracts (high-margin concentrates wholesale) brands. The successful Health for Life brand operates in the rapidly growing Phoenix Metropolitan Statistical Area.  With the acquisition of The Holistic Center, MPX added another operating medical cannabis enterprise to its footprint in Arizona.

GreenMart of Nevada NLV, LLC (“GreenMart NV”) is an award winning licensed cultivation, production and wholesale business, licensed for both the medical and “adult use” sectors in Las Vegas, Nevada, and is already selling wholesale into the Nevada medical cannabis market. GreenMart NV has also optioned suitable locations and intends to enter the higher-margin retail arena by applying for at least two dispensary licenses in the Las Vegas market which will operate under the “Health for Life” brand.

In Massachusetts, MPX is building out and will operate a cultivation and production facility as well as up to three dispensaries and manages three full service dispensaries and one producer in Maryland.

In Canada, MPX has acquired Canveda, which has received its cultivation license from Health Canada, will operate a cultivation and production facility in Peterborough, Ontario. The Company also leases a property in Owen Sound, Ontario, for which an application to Health Canada has been made for a cannabis production and sales license. In addition, the Company will continue its efforts to develop its legacy nutraceuticals business.

About Salus BioPharma

Salus BioPharma manufactures and markets pharmacy grade cannabis-based products developed with partner, Panaxia. All products are manufactured to GMP standards and provide accurate, specific and reproducible dosing.

About Panaxia

Panaxia is a pharmaceutical company that is part of a group of leading Israeli pharmaceutical companies with more than four decades of experience and proven success, specializing in medical cannabis R&D and manufacturing.

Cautionary Statement Regarding Forward-Looking Information

This news release includes certain “forward-looking statements” under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, MPX’s objectives and intentions.  Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; delay or failure to receive board, shareholder or regulatory approvals; those additional risks set out in MPX’s public documents filed on SEDAR at www.sedar.com; and other matters discussed in this news release. Although MPX believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, MPX disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

On behalf of the Board of Directors

MPX Bioceutical Corporation (formerly The Canadian Bioceutical Corporation)
W. Scott Boyes, Chairman, President and CEO

For further information, please contact:

MPX Bioceutical Corporation (formerly The Canadian Bioceutical Corporation)
W. Scott Boyes, Chairman, President and CEO
T: +1-416-840-3725
info@mpxbioceutical.com
www.mpxbioceutical.com

Media Contact:
Anne Donohoe
KCSA Strategic Communications
212-896-1265
adonohoe@kcsa.com  

Investor Contact:
Phil Carlson / Elizabeth Barker
KCSA Strategic Communications
212-896-1233 / 212-896-1203
pcarlson@kcsa.com / ebarker@kcsa.com